Unbiased Analysis of Today's Healthcare Issues
That is the title of a paper published today with my co-authors Felicia Forma, Kevin Chiu, Jason Shafrin, Dusica Hadzi Boskovic, and S Phani Veeranki. The subtitle is: Caregiver preferences for health technology tools to monitor medication adherence among patients with serious mental illness. The paper abstract is below: Background Adherence to antipsychotic medication is…
For any patients–but especially those with neurodevelopmental illnesses such as schizophrenia–have a consistent ‘medical home’ is vital for continuity of care. However, having consistent access to provider who know your medical history may be challenging if you frequently switch health insurance. “Insurance churn” is defined a patients who either transition between health plans or transition…
That is the finding from a white paper from the Schizophrenia and Psychosis Action Alliance titled “Societal Costs of Schizophrenia & Related Disorders“. I am a co-author on the paper. Below is a summary of the findings: …the societal costs of schizophrenia were estimated to be $281.6 billion in 2020…Direct costs for individuals living with…
As COVID-19 has made many of us acutely aware, providing high quality mental health care is vital. However, the mental health care market is a difficult one for insurers; there is evidence that uncertainty and variation in treatments are greater compared to physical health conditions (for instance, see Frank et al. 2000). Thus uncertainty and…
This is the title of a paper published today with co-authors Suepattra May, Caroline Huber, Meaghan Roach, Wade Aubry, Darius Lakdawalla, John Kane, and Felicia Forma. The subtitle is “Qualitative Case Study of Glucose Monitoring Technology“. The abstract is below. Background: Evaluation of patients with serious mental illness (SMI) relies largely on patient or caregiver…
That is the key takeaway from a recent JAMA Viewpoint by Carlo, Barnett and Frank (2020). While there has been some progress, there are still tremendous gaps that need to be addressed. For patients with schizophrenia, bipolar disorder, or other more serious mental health conditions, less than two-thirds received care for their illness, according to…
The the health and economic of serious mental illness (SMI) is often overlooked by the health policy and some provider communities. One key question is how how can we quantify the economic burden of SMI. Further, how can we reduce this burden. Much of my research has looked at how medications can improve health and…
Access to physician services and pharmaceuticals is vital–particularly among patients with serious mental illness–to insure patients receive the care they need. However, the likelihood patients receive this care depends on where they live. A paper by Manchester (2018) examines a cohort of patients eligible for both Medicare and U.S. Social Security Disability Insurance (SSDI) and…
Pharmafile has an interesting article on the “Economics of Mental Health”. The article has a number of interesting statistics: The cost: “Mental health issues have been estimated to cost the world economy $2.5 trillion each year. To put that into perspective, the United Kingdom’s gross domestic product (GDP) was $2.6 trillion in 2017.” Costs extend…
This is the topic of a recent publication with co-authors Kata Bognar, Katie Everson, Michelle Brauer, Darius Lakdawalla and Felicia Forma. The full title is Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness. The abstract is below, but do read the whole thing…